Demand for Advanced Pancreatic Cancer Treatments at All Time High as Promising Options Come into Focus
22 janv. 2025 08h30 HE
|
FN Media Group LLC
PALM BEACH, Fla., Jan. 22, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The demand for effective pancreatic cancer treatments is and has been undeniably high. The growing number of...
University Cancer & Blood Center physicians recognized among Atlanta’s Top Doctors in Modern Luxury Medicine + Doctors magazine
15 janv. 2025 14h14 HE
|
University, Cancer and Blood Center
Four physicians from University Cancer & Blood Center are recognized as Top Doctors in Modern Luxury Medicine + Doctors magazine.
Immuneering Provides Positive Update on Phase 2a Arm Studying IMM-1-104 in Combination with Modified FOLFIRINOX for First-Line Pancreatic Cancer
13 janv. 2025 08h00 HE
|
Immuneering Corporation
Immuneering Provides Positive Update on Phase 2a Arm Studying IMM-1-104 in Combination with Modified FOLFIRINOX for First-Line Pancreatic Cancer
Immuneering Announces Positive Data Update from Three Pancreatic Cancer Arms of Ongoing Phase 2a Trial of IMM-1-104; Plans to Expand Trial with Additional Arms
07 janv. 2025 07h00 HE
|
Immuneering Corporation
Immuneering Announces Positive Data Update from Three Pancreatic Cancer Arms of Ongoing Phase 2a Trial of IMM-1-104
Achievements and Progress Heading into 2025 for Oncology Treatments and Therapies Fuel an Optimistic Outlook
26 déc. 2024 09h00 HE
|
FN Media Group LLC
PALM BEACH, Fla., Dec. 26, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The breast cancer drugs market is experiencing rapid expansion due to the diverse applications of drugs in...
Immuneering Launches Pancreatic Cancer Advisory Board
19 déc. 2024 08h00 HE
|
Immuneering Corporation
Immuneering Launches Pancreatic Cancer Advisory Board
Promising Data for Treating Gastrointestinal Cancer Leading to Hopeful Advancements for Pancreatic & Anal Cancers
18 déc. 2024 08h45 HE
|
FN Media Group LLC
PALM BEACH, Fla., Dec. 18, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - One of the most common malignancies in the world today is gastric cancer. The incidence rate is influenced by...
Immuneering to Present Data from Three Arms of its Ongoing Phase 2a Trial of IMM-1-104 in Early January 2025
17 déc. 2024 08h00 HE
|
Immuneering Corporation
Immuneering to Present Data from Three Arms of its Ongoing Phase 2a Trial of IMM-1-104 in Early January 2025
Immuneering to Present at the Piper Sandler 36ᵗʰ Annual Healthcare Conference
27 nov. 2024 08h00 HE
|
Immuneering Corporation
Immuneering to Present at the Piper Sandler 36th Annual Healthcare Conference
Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates
13 nov. 2024 16h05 HE
|
Immuneering Corporation
Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates